Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $8,541 | $8,056 | $7,679 | $7,190 |
| % Growth | 6% | 4.9% | 6.8% | – |
| Cost of Goods Sold | $714 | $875 | $887 | $1,012 |
| Gross Profit | $7,827 | $7,181 | $6,792 | $6,178 |
| % Margin | 91.6% | 89.1% | 88.4% | 85.9% |
| R&D Expenses | $16,334 | $20,897 | $23,987 | $26,257 |
| G&A Expenses | $0 | $13,567 | $0 | $15,722 |
| SG&A Expenses | $12,573 | $16,710 | $18,626 | $15,358 |
| Sales & Mktg Exp. | $0 | $3,143 | $0 | -$364 |
| Other Operating Expenses | $0 | $0 | $36 | $0 |
| Operating Expenses | $28,907 | $37,607 | $42,613 | $41,615 |
| Operating Income | -$21,080 | -$32,236 | -$35,821 | -$35,437 |
| % Margin | -246.8% | -400.1% | -466.5% | -492.9% |
| Other Income/Exp. Net | -$3,145 | -$3,592 | -$2,848 | -$6,332 |
| Pre-Tax Income | -$24,225 | -$35,828 | -$38,669 | -$41,769 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24,225 | -$35,828 | -$38,669 | -$41,769 |
| % Margin | -283.6% | -444.7% | -503.6% | -580.9% |
| EPS | -0.42 | -0.63 | -0.68 | -0.74 |
| % Growth | 33.3% | 7.4% | 8.1% | – |
| EPS Diluted | -0.42 | -0.63 | -0.68 | -0.74 |
| Weighted Avg Shares Out | 57,229 | 57,064 | 56,852 | 56,688 |
| Weighted Avg Shares Out Dil | 57,229 | 57,064 | 56,852 | 56,688 |
| Supplemental Information | – | – | – | – |
| Interest Income | $598 | $1,109 | $1,462 | $1,747 |
| Interest Expense | $3,843 | $4,617 | $4,346 | $4,298 |
| Depreciation & Amortization | $134 | $140 | $131 | $125 |
| EBITDA | -$21,080 | -$31,071 | -$34,192 | -$37,346 |
| % Margin | -246.8% | -385.7% | -445.3% | -519.4% |